NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-18-923 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches are encouraged. This FOA seeks to stimulate innovative research in deciphering immune mechanisms in humans required for protection from Mtb infection or tuberculosis (TB) disease, or induced by TB vaccines that go beyond what have traditionally been investigated in TB.
Funding Opportunity PAR-18-925 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity? Announcement (FOA) is to request research applications that test innovative approaches to improve diabetes and obesity prevention and/or treatment in healthcare settings where individuals receive their medical care?. Research applications should be designed to test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches with the potential to be broadly disseminated outside the specific setting where it is being tested. The goal of the research is to obtain results that will improve healthcare practice and inform healthcare policy for the prevention or management of these conditions. Therefore, interventions must be integrated into the existing healthcare structure and/or processes. The healthcare setting may not be used solely as a venue for recruitment.
Notice NOT-HS-18-016 from the NIH Guide for Grants and Contracts
Notice NOT-TR-18-032 from the NIH Guide for Grants and Contracts
Notice NOT-HD-18-019 from the NIH Guide for Grants and Contracts
Notice NOT-AR-19-009 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-085 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-077 from the NIH Guide for Grants and Contracts
Notice NOT-HD-18-016 from the NIH Guide for Grants and Contracts
Notice NOT-MD-18-016 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-18-510 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)s Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) conducts multi-site, multi-disciplinary studies of Lower Urinary Tract Dysfunction (LUTD) to better define clinical phenotype, to better describe the impact and diversity of symptoms, and to develop new patient-centric tools for improved measurement of clinical symptoms, all with the goals of informing future clinical studies and improving patient care. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite applications from current LURN Research Sites for a second five-year Project Period.
Funding Opportunity RFA-DK-18-511 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)s Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) conducts multi-site, multi-disciplinary studies of Lower Urinary Tract Dysfunction (LUTD) to better define clinical phenotype, to better describe the impact and diversity of symptoms, and to develop new patient-centric tools for improved measurement of clinical symptoms, all with the goals of informing future clinical studies and improving patient care. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to solicit applications from the current LURN Data Coordinating Center for a second five-year Project Period.
Funding Opportunity RFA-DK-18-513 from the NIH Guide for Grants and Contracts. The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network conducts multi-center studies of urologic chronic pelvic pain syndrome (UCPPS), a term used to encompass interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The goal of the MAPP Network is to provide new insights into underlying pathophysiology, natural history, clinical phenotype, and risk factors as a foundation for future clinical intervention efforts and ultimately to improve clinical management. The MAPP Research Network is currently comprised of nine Discovery Sites, a Data Coordination Core (DCC), and a Tissue and Technology Core (TATC). The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite applications from the current six major MAPP Discovery Sites (awarded through RFA-DK-13-507) for an additional three-year project period. During this period, the MAPP Network will continue collection of longitudinal phenotypic data and biological samples from UCPPS participants currently enrolled in the Trans-MAPP Symptoms Patterns Study protocol and continue to conduct highly-collaborative, integrated data analyses for identification of new insights into UCPPS.
Funding Opportunity RFA-DK-18-514 from the NIH Guide for Grants and Contracts. The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network conducts multi-center studies of urologic chronic pelvic pain syndrome (UCPPS), a term used to encompass interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The goal of the MAPP Network is to provide new insights into underlying pathophysiology, natural history, clinical phenotype, and risk factors as a foundation for future clinical intervention efforts and ultimately to improve clinical management. The MAPP Research Network is currently comprised of nine Discovery Sites, a Data Coordination Core (DCC), and a Tissue and Technology Core (TATC). The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite an application from the current MAPP Network DCC for an additional three-year project period. During this period, the MAPP Network will continue collection of longitudinal phenotypic data and biological samples from UCPPS participants currently enrolled in the Trans-MAPP Symptoms Patterns Study and continue to conduct highly-collaborative, integrated data analyses for identification of new insights into UCPPS.
Funding Opportunity RFA-DK-18-515 from the NIH Guide for Grants and Contracts. The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network conducts multi-center studies of urologic chronic pelvic pain syndrome (UCPPS), a term used to encompass interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The goal of the MAPP Network is to provide new insights into underlying pathophysiology, natural history, clinical phenotype, and risk factors as a foundation for future clinical intervention efforts and ultimately to improve clinical management. The MAPP Research Network is currently comprised of nine Discovery Sites, a Data Coordination Core (DCC), and a Tissue and Technology Core (TATC). The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite an application from the current MAPP Network TATC for an additional three-year project period. During this period, the MAPP Network will continue collection of longitudinal phenotypic data and biological samples from UCPPS participants currently enrolled in the Trans-MAPP Symptoms Patterns Study and continue to conduct highly-collaborative, integrated data analyses for identification of new insights into UCPPS.
Notice NOT-OD-18-229 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-227 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-228 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-18-029 from the NIH Guide for Grants and Contracts. The purpose of this RFA is to support early clinical trials consortia poised to efficiently evaluate the biologic effects of cancer preventive agents and to determine clinically-relevant correlates in order to advance their development for cancer prevention. The program objectives are: To efficiently design and conduct early phase clinical trials to assess the cancer preventive potential of NCI-sponsored agents of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials. To characterize the effects of these agents on the molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlate these effects with clinical endpoints. To develop further scientific insights into the mechanism of cancer prevention by the agent examined and continue to develop novel potential markers as determinants of response.
Funding Opportunity RFA-CA-18-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of the National Cancer Institute (NCI) initiative intended to support Cancer Prevention Clinical Trials Network (CP-CTNet). The goals for the CP-CTNet include: Design and conduct early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials; Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints. Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response. CP-CTNet consists of two types of components: Five CP-CTNet Sites (covered by companion FOA, RFA-CA-18-029); and One CP-CTNet Data Management, Auditing, and Coordinating Center (DMACC, covered via this FOA). The CP-CTNet Sites will provide scientific leadership in development and conduct of early phase cancer prevention clinical trials as well as manage and analyze the data. The DMACC will support the CP-CTNet Sites and coordinate trans-Network activities with the following specific responsibilities: (i) centralized data management and data reporting, (ii) clinical trials auditing, and (iii) administrative and logistical coordination across CP-CTNet.